Drug Information

Drug (ID: DG01101) and It's Reported Resistant Information

• Name: Midecamycin
• Synonyms: Midecamycin; Rubimycin; Espinomycin A; Platenomycin B1; Turimycin P3; Medecamycin A1; Mydecamycin; 35457-80-8; Midecamycin A1; Medemycin; UNII-N34Z0Y5UH7; Antibiotic SF 837; N34Z0Y5UH7; SF 837; Madecacine; Midecamicina; Midecamycine; Midecamycinum; YL 704 B1; Macro-Dil; Antibiotic SF-837; Turimycin P(sub 3); Midecamycin A(sub 1); Antibiotic SF 837 A1; Antibiotic YL 704 B1; Midecamycine [INN-French]; Midecamycinum [INN-Latin]; NSC 154011; Midecamicina [INN-Spanish]; Midecamycin [INN:DCF:JAN]; Midecamycin,(S); Medemycin (TN); NCGC00016830-01; EINECS 252-578-0; CAS-35457-80-8; Midecamycin (JP17/INN); DSSTox_CID_25463; DSSTox_RID_80894; DSSTox_GSID_45463; SCHEMBL141581; CHEMBL444963; DTXSID5045463; CHEBI:31845; C41H67NO15; (4R,5S,6S,7R,9R,10R,11E,13E,16R)-6-(((2S,3R,4R,5S,6R)-4-(dimethylamino)-3-hydroxy-5-(((2S,4R,5S,6S)-4-hydroxy-4,6-dimethyl-5-(propionyloxy)tetrahydro-2H-pyran-2-yl)oxy)-6-methyltetrahydro-2H-pyran-2-yl)oxy)-10-hydroxy-5-methoxy-9,16-dimethyl-2-oxo-7-(2-oxoethyl)oxacyclohexadeca-11,13-dien-4-yl propionate; ACT02621; HY-B1908; Tox21_110635; s5560; AKOS022185298; ZINC169368401; CCG-270507; CS-5909; DB13456; Leucomycin V, 3,4(sup B)-dipropanoate; Leucomycin V, 3,4B-dipropanoate (9CI); D01339; H10500; Midecamycin), Antibiotic for Culture Media Use Only; Q2636110; W-106669; 7-(Formylmethyl)-4,10-dihydroxy-5-methoxy-9,16-dimethyl-2-oxooxacyclohexadeca-11,13-dien-6-yl 3,6-dideoxy-4-O-(2,6-dideoxy-3-C-methyl-alpha-L-ribo-hexopyranosyl)-3-(dimethylamino)-beta-D-glucopyranoside 4',4''-dipropionate (ester); 7-(Formylmethyl)-4,10-dihydroxy-5-methoxy-9,16-dimethyl-2-oxooxacyclohexadeca-11,13-dien-6-yl 3,6-dideoxy-4-O-(2,6-dideoxy-3-C-methyl-alpha-L-ribo-hexopyranosyl)-3-(dimethylamino)-beta-D-glucopyranoside 4',4'-dipropionate (ester)
• Indication:
  In total 1 Indication(s)
  Bacterial infection [ICD-11: 1A00-1C4Z]; Investigative; [1]
• Drug Resistance Disease(s):
  Disease(s) with Resistance Information Validated by in-vivo Model for This Drug (4 diseases)
  Bacterial infection [ICD-11: 1A00-1C4Z]; [2]
  Otitis media [ICD-11: AA80]; [1]
  Sepsis [ICD-11: 1G40]; [1]
  Staphylococcus meningitis [ICD-11: 1B54]; [1]
• Target: .; NOUNIPROTAC; [1]
• Formula: C41H67NO15
• IsoSMILES: CCC(=O)O[C@@H]1CC(=O)O[C@@H](C/C=C/C=C/[C@@H]([C@@H](C[C@@H]([C@@H]([C@H]1OC)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)C)O[C@H]3C[C@@]([C@H]([C@@H](O3)C)OC(=O)CC)(C)O)N(C)C)O)CC=O)C)O)C
• InChI: 1S/C41H67NO15/c1-11-30(45)54-29-21-32(47)51-24(4)16-14-13-15-17-28(44)23(3)20-27(18-19-43)37(38(29)50-10)57-40-35(48)34(42(8)9)36(25(5)53-40)56-33-22-41(7,49)39(26(6)52-33)55-31(46)12-2/h13-15,17,19,23-29,33-40,44,48-49H,11-12,16,18,20-22H2,1-10H3/b14-13+,17-15+/t23-,24-,25-,26+,27+,28+,29-,33+,34-,35-,36-,37+,38+,39+,40+,41-/m1/s1
• InChIKey: DMUAPQTXSSNEDD-QALJCMCCSA-N
• PubChem CID: 5282169
• ChEBI ID: CHEBI:31845
• TTD Drug ID: D0J7OG
• DrugBank ID: DB13456

Type(s) of Resistant Mechanism of This Drug

  DISM: Drug Inactivation by Structure Modification

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-01: Infectious/parasitic diseases

Bacterial infection [ICD-11: 1A00-1C4Z]

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Drug Inactivation by Structure Modification (DISM)

Key Molecule: Oleandomycin glycosyltransferase oleD (OLED) [1]

• Molecule Alteration: Expression; Acquired
• Resistant Disease: Bacillus intestinalis infection [ICD-11: 1A00-1C4Z]
• Experimental Note: Discovered Using In-vivo Testing Model
• In Vitro Model: Bacillus intestinalis strain T30; 1963032
• Experiment for Molecule Alteration: SDS-PAGE analysis
• Experiment for Drug Resistance: Broth microdilution antifungal susceptibility test assay

Key Molecule: Oleandomycin glycosyltransferase oleD (OLED) [1]

• Molecule Alteration: Missense mutation; p.Q327A
• Resistant Disease: Bacillus intestinalis infection [ICD-11: 1A00-1C4Z]
• Experimental Note: Discovered Using In-vivo Testing Model
• In Vitro Model: Bacillus intestinalis strain T30; 1963032
• Experiment for Molecule Alteration: SDS-PAGE analysis
• Experiment for Drug Resistance: Broth microdilution antifungal susceptibility test assay

Key Molecule: Oleandomycin glycosyltransferase oleD (OLED) [1]

• Molecule Alteration: Missense mutation; p.Q327F
• Resistant Disease: Bacillus intestinalis infection [ICD-11: 1A00-1C4Z]
• Experimental Note: Discovered Using In-vivo Testing Model
• In Vitro Model: Bacillus intestinalis strain T30; 1963032
• Experiment for Molecule Alteration: SDS-PAGE analysis
• Experiment for Drug Resistance: Broth microdilution antifungal susceptibility test assay

Staphylococcus meningitis [ICD-11: 1B54]

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Drug Inactivation by Structure Modification (DISM)

Key Molecule: Oleandomycin glycosyltransferase oleD (OLED) [1]

• Molecule Alteration: Expression; Acquired
• Resistant Disease: Staphylococcus aureus infection [ICD-11: 1B54.0]
• Experimental Note: Discovered Using In-vivo Testing Model
• In Vitro Model: Pseudomonas aeruginosa strain B-2099/18; 287
• Experiment for Molecule Alteration: SDS-PAGE analysis
• Experiment for Drug Resistance: Broth microdilution antifungal susceptibility test assay

Sepsis [ICD-11: 1G40]

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Drug Inactivation by Structure Modification (DISM)

Key Molecule: Oleandomycin glycosyltransferase oleD (OLED) [1]

• Molecule Alteration: Expression; Acquired
• Resistant Disease: Sepsis [ICD-11: 1G40.0]
• Experimental Note: Discovered Using In-vivo Testing Model
• In Vitro Model: T7 express cells; Lung; Mus musculus (Mouse); CVCL_4314
• Experiment for Molecule Alteration: SDS-PAGE analysis
• Experiment for Drug Resistance: Broth microdilution antifungal susceptibility test assay

ICD-10: Ear/mastoid process diseasess

Otitis media [ICD-11: AA80]

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Drug Inactivation by Structure Modification (DISM)

Key Molecule: Oleandomycin glycosyltransferase oleD (OLED) [1]

• Molecule Alteration: Expression; Acquired
• Resistant Disease: Pseudomonas aeruginosa infection [ICD-11: 1A00-1C4Z]
• Experimental Note: Discovered Using In-vivo Testing Model
• In Vitro Model: Prostate cancer tissue; N.A.
• Experiment for Molecule Alteration: SDS-PAGE analysis
• Experiment for Drug Resistance: Broth microdilution antifungal susceptibility test assay

References

• Ref 1: Midecamycin Is Inactivated by Several Different Sugar Moieties at Its Inactivation Site .Int J Mol Sci. 2021 Nov 23;22(23):12636. doi: 10.3390/ijms222312636. 10.3390/ijms222312636
• Ref 2: Inactivation of the macrolide antibiotics erythromycin, midecamycin, and rokitamycin by pathogenic Nocardia species .Antimicrob Agents Chemother. 1994 Sep;38(9):2197-9. doi: 10.1128/AAC.38.9.2197. 10.1128/AAC.38.9.2197